Wednesday, May 1, 2013

May Day protests: From Bangladesh to Europe, angry workers rally in the tens of thousands (+video)

But this year's May Day demonstrations come on the heels of the tragic Bangladesh factory collapse, a potent symbol for many of the importance of workers' rights.

By Ryan Lenora Brown,?Correspondent / May 1, 2013

Workers and protesters hold a huge banner march to the government office during a May Day rally in Hong Kong, Wednesday. Hundreds of workers, local labor right groups, and striking dockworkers join the annual rally to demand better wages and working conditions.

Vincent Yu/AP

Enlarge

In Dhaka, Bangladesh, a raucous crowd descended on the city center with signs and drums, chanting and waving banners demanding the death penalty for the owner of a factory where more than 400 people died in a building collapse last week.

Skip to next paragraph Ryan Lenora Brown

Correspondent

Ryan Brown edits the Africa Monitor blog and contributes to the national and international news desks of the Monitor. She is a former Fulbright fellow to South Africa and holds a degree in history from Duke University.?

Recent posts

' + google_ads[0].line2 + '
' + google_ads[0].line3 + '

'; } else if (google_ads.length > 1) { ad_unit += ''; } } document.getElementById("ad_unit").innerHTML += ad_unit; google_adnum += google_ads.length; return; } var google_adnum = 0; google_ad_client = "pub-6743622525202572"; google_ad_output = 'js'; google_max_num_ads = '1'; google_feedback = "on"; google_ad_type = "text"; google_adtest = "on"; google_image_size = '230x105'; google_skip = '0'; // --> As marches take place around the world to mark Labour Day, in the Spanish capital hundreds gathered to protest against the economic crisis that has driven the country?s unemployment rate above 27 percent.

In Jakarta, Indonesia, some of the tens of thousands of demonstrators marching through the city came dressed as ants ? complete with bright red outfits and antennae ? to depict the exploitation of workers.?

And in Greece, trains, buses, and ferries sat vacant and hospitals nearly empty as thousands of public sector employees walked off the job in a one-day strike.

Each year, May 1, better known as May Day, is marked with labor rallies and strikes around the world. And this year's holiday came at a particularly prescient moment in many parts of the world.?

From Europe, where the bite of austerity has left many facing down unemployment and reduced benefits, to South and Southeast Asia, a region cluttered with precariously-built factories similar to the one that collapsed last week in Bangladesh, demonstrators gathered to vent outrage and demand reform.

?My brother has died. My sister has died. Their blood will not be valueless,? yelled one Bangladeshi protestor through a crackling loudspeaker, according to the Associated Press.

As the march wove through downtown Dhaka, rescue workers in the industrial suburb of Savar continued their search for bodies and survivors in the rubble of Rana Plaza, which collapsed suddenly on April 24 with thousands of garment workers inside.

The disaster at the factory, which manufactured clothing for several low-end Western retailers, touched off global outrage about the working conditions of garment workers across the developing world. In Phnom Pehn, Cambodia, workers rallied for higher wages and safer working conditions. In Manila, Philipines, where labor unions are banned, workers marched to demand the right to organize. And in Hong Kong, thousands turned out in support of striking dock workers, calling for wages that would help close the income gap between the country?s rich and its poor.

And that was all before Europe woke up.

There has "never been a May 1 with more reason to take to the streets,? one Spanish union leader told Reuters during a march in Madrid this morning, where protestors carried signs reading "austerity ruins and kills" and "reforms are robbery.? (Read the Monitor's feature about how Spaniards are increasingly flocking to the countryside to cut costs and find new jobs.)

In Greece, where the government recently announced that it would lay off 180,000 civil servants over the next two years ? the first such cuts in 100 years ? a strike shut down public transit across Athens. ?

And in France, which saw unemployment rose again last month, marchers carried banners reading, ?It?s too much! Alternatives exist? and ?Where are the real socialists in our government??

An exception to the doom and gloom of this year?s May Day was Russia, where a festive celebration of the holiday harks back to Soviet times. Indeed, many of those who gathered in the streets of Moscow were buoyant, Euronews reported.

?The atmosphere is excellent. It?s a holiday for us, the beginning of something new, bright, and joyful,? one demonstrator told reporters.

May 1 is a national holiday in some 80 countries around the world, and its ties to labor advocacy date back to 1886, when American police killed 10 protestors at a rally for an eight-hour workday in Chicago?s Haymarket Square. International socialist organization and labor unions declared it a day of commemoration and action soon after.

Ironically, however, May Day is not celebrated in the United States. In the early 1890s, fearing the ?socialist? overtones of the holiday, President Grover Cleveland quickly declared an alternate holiday, beginning the American tradition of celebrating Labor Day on the first Monday of September.?

Source: http://rss.csmonitor.com/~r/csmonitor/globalnews/~3/WmYU4gZ7dUc/May-Day-protests-From-Bangladesh-to-Europe-angry-workers-rally-in-the-tens-of-thousands-video

Boston Marathon Explosion Boston Marathon bombing irs new york times Friends Reunion Elena Delle Donne usa today

Large genomic study identifies endometrial cancer subtypes, treatment opportunities

Large genomic study identifies endometrial cancer subtypes, treatment opportunities [ Back to EurekAlert! ] Public release date: 1-May-2013
[ | E-mail | Share Share ]

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center

NEW YORK, MAY 1, 2013 Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.

Published in the May 2 issue of the journal Nature, the findings may help doctors more accurately diagnose endometrial cancer and choose treatments that will target genomic mutations in women with endometrioid and uterine serous adenocarcinomas, the two most common types of endometrial cancer. The findings could also guide clinical trials and the development of new drugs.

"These findings have an immediate therapeutic application, as patients with endometrial cancer can be tested routinely to see whether they qualify for a targeted therapy clinical trial," said Memorial Sloan-Kettering gynecologic oncologist Douglas A. Levine, MD, corresponding author on the study, principal investigator of Memorial Sloan-Kettering's TCGA Tissue Source Site, and Co-Chair of TCGA's Endometrial Working Group. "The current landscape of treatment for endometrial cancer is quite chaotic, and this research may provide order to that landscape, especially for more-aggressive endometrial cancers."

Endometrial cancer, which forms in the tissues lining the uterus, is the fourth leading type of cancer among women and the eighth leading cause of cancer death. Endometrioid tumors are usually less aggressive, while uterine serous tumors are more aggressive.

There has been little agreement among doctors over the best treatment approach following surgery for patients with a high risk of recurrence, with decisions relying largely on a tumor's pathology. However, it is difficult for pathologists to reliably differentiate high-grade endometrioid tumors from uterine serous tumors.

According to Dr. Levine, incorporating new genomic information into treatment planning could be a great leap forward, helping to make certain that additional therapies are used effectively and only when necessary.

The analysis of 373 endometrial tumors showed that approximately a quarter of high-grade endometrioid tumors have certain types of genomic alterations also found in uterine serous tumors. This suggests that a significant portion of endometrioid tumors should be treated more aggressively after surgery.

Many of the tumors analyzed had mutations in important cancer-related genes and pathways for which targeted therapies are already being tested in clinical trials for other cancers. For example, 84 percent of the tumors have some alteration in the PI3 kinase pathway, which is implicated in many cancers. Additionally, genomic alterations in uterine serous tumors share many features with ovarian serous and triple-negative breast cancers, suggesting opportunity for shared treatments.

Investigators at Memorial Sloan-Kettering are now translating these findings into clinically useful tests that may be applied to ongoing and planned clinical trials.

A project jointly funded by the National Cancer Institute and the National Human Genome Research Institute, TCGA is one of the most comprehensive national efforts to collect and analyze the largest set of tumor samples to date using state-of-the-art genomic and molecular techniques. Memorial Sloan-Kettering currently houses one of TCGA's Genome Data Analysis Centers, led by computational biologist Chris Sander, PhD, biocomputing manager Nikolaus Schultz, PhD, and molecular pathologist Marc Ladanyi, MD. For the endometrial cancer study, Memorial Sloan-Kettering contributed more than 10 percent of all tissue samples analyzed.

###

This research was supported by the National Cancer Institute of the National Institutes of Health (NIH) under awards 5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04, U54HG003067-11, U54HG003079-10, and U54HG003273-10, and supplemented by the Recovery Act.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to http://www.mskcc.org.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Large genomic study identifies endometrial cancer subtypes, treatment opportunities [ Back to EurekAlert! ] Public release date: 1-May-2013
[ | E-mail | Share Share ]

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center

NEW YORK, MAY 1, 2013 Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.

Published in the May 2 issue of the journal Nature, the findings may help doctors more accurately diagnose endometrial cancer and choose treatments that will target genomic mutations in women with endometrioid and uterine serous adenocarcinomas, the two most common types of endometrial cancer. The findings could also guide clinical trials and the development of new drugs.

"These findings have an immediate therapeutic application, as patients with endometrial cancer can be tested routinely to see whether they qualify for a targeted therapy clinical trial," said Memorial Sloan-Kettering gynecologic oncologist Douglas A. Levine, MD, corresponding author on the study, principal investigator of Memorial Sloan-Kettering's TCGA Tissue Source Site, and Co-Chair of TCGA's Endometrial Working Group. "The current landscape of treatment for endometrial cancer is quite chaotic, and this research may provide order to that landscape, especially for more-aggressive endometrial cancers."

Endometrial cancer, which forms in the tissues lining the uterus, is the fourth leading type of cancer among women and the eighth leading cause of cancer death. Endometrioid tumors are usually less aggressive, while uterine serous tumors are more aggressive.

There has been little agreement among doctors over the best treatment approach following surgery for patients with a high risk of recurrence, with decisions relying largely on a tumor's pathology. However, it is difficult for pathologists to reliably differentiate high-grade endometrioid tumors from uterine serous tumors.

According to Dr. Levine, incorporating new genomic information into treatment planning could be a great leap forward, helping to make certain that additional therapies are used effectively and only when necessary.

The analysis of 373 endometrial tumors showed that approximately a quarter of high-grade endometrioid tumors have certain types of genomic alterations also found in uterine serous tumors. This suggests that a significant portion of endometrioid tumors should be treated more aggressively after surgery.

Many of the tumors analyzed had mutations in important cancer-related genes and pathways for which targeted therapies are already being tested in clinical trials for other cancers. For example, 84 percent of the tumors have some alteration in the PI3 kinase pathway, which is implicated in many cancers. Additionally, genomic alterations in uterine serous tumors share many features with ovarian serous and triple-negative breast cancers, suggesting opportunity for shared treatments.

Investigators at Memorial Sloan-Kettering are now translating these findings into clinically useful tests that may be applied to ongoing and planned clinical trials.

A project jointly funded by the National Cancer Institute and the National Human Genome Research Institute, TCGA is one of the most comprehensive national efforts to collect and analyze the largest set of tumor samples to date using state-of-the-art genomic and molecular techniques. Memorial Sloan-Kettering currently houses one of TCGA's Genome Data Analysis Centers, led by computational biologist Chris Sander, PhD, biocomputing manager Nikolaus Schultz, PhD, and molecular pathologist Marc Ladanyi, MD. For the endometrial cancer study, Memorial Sloan-Kettering contributed more than 10 percent of all tissue samples analyzed.

###

This research was supported by the National Cancer Institute of the National Institutes of Health (NIH) under awards 5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04, U54HG003067-11, U54HG003079-10, and U54HG003273-10, and supplemented by the Recovery Act.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to http://www.mskcc.org.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-05/mscc-lgs050113.php

Alaska earthquake green bay packers houston texans houston texans Joe Webb Fiesta Bowl Jeanie Buss

Uber CEO Kalanick Denies Pitching Investors For Funding At A $1B Valuation

Travis Kalanick HeadshotUber CEO Travis Kalanick said that he hasn’t spoken to investors in a year and half about raising capital, denying reports that the company is raising funding at a $1 billion valuation. Reuters reported that story earlier today, citing one source. We had heard similar rumors over the past few weeks but they weren’t substantiated enough to report. That said, just because Kalanick isn’t speaking to investors about raising money, doesn’t mean that VCs or private equity firms aren’t courting him to take their money. The company, which pioneered on-demand taxi and black cab rides directly from your mobile phone, has raised nearly $50 million to date. The most recent $37 million round was led by Menlo Ventures, which aggressively outbid other competitors on valuation to win the deal. Bill Gurley, a general partner at Benchmark Capital, which came in on Uber’s Series A round, said the company is growing faster than eBay. Uber now lists about 30 different geographic locations around the world where it operates. The company started out with black cabs, then went into environmentally friendly vehicles and then regular cabs. But now it’s making its headway into ride-sharing to compete head-to-head with startups like Zimride’s Lyft and Sidecar, which don’t have the same overhead costs and fees as Uber does. With its original black cab model, Uber partnered with third-party limo and taxi services to provide rides, while Sidecar and Lyft hire regular people with cars who want to earn extra income by driving passengers around. All of these companies, along with Hailo in the U.K. and Europe, and even Chinese taxi apps like DiDi, tie into a global wave of disruption around urban transportation. .@uber hasn’t spoken to a single investor about raising $ since Nov ’11. Any reports to the contrary (i.e. Reuters) are completely false ? travis kalanick (@travisk) April 30, 2013

Source: http://feedproxy.google.com/~r/Techcrunch/~3/OOCRuZHJR8o/

mexico city mexico earthquake aziz ansari aziz ansari katherine jenkins peyton manning broncos mexico city earthquake